A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)
- Resource Type
- article
- Source
- Frontiers in Oncology, Vol 14 (2024)
- Subject
pembrolizumab non-small cell lung cancer real-world data immunotherapy observational study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2234-943X